Journal
PHARMACEUTICS
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13081270
Keywords
glioblastoma; blood-brain barrier; ultrasound; temozolomide; liposome
Categories
Funding
- National Key R&D Program of China [2018YFC0115900, 2020YFA0908800]
- National Natural Science Foundation of China [81871376, 81660381]
- Guangdong Innovation Platform of Translational Research for Cerebrovascular Diseases
- Shenzhen Science and Technology Innovation Committee [JCYJ20180507182420114, JCYJ20190812171820731, ZDSYS201802061806314]
Ask authors/readers for more resources
The ultrasound-mediated BBB opening combined with liposomal temozolomide formulation has been successfully applied in the treatment of glioblastoma, significantly inhibiting tumor growth and prolonging animal survival time without significant side effects.
Glioblastoma (GBM) is the commonest form of primary brain tumor in the central nervous system, with median survival below 15 months and only a 25% two-year survival rate for patients. One of the major clinical challenges in treating GBM is the presence of the blood-brain barrier (BBB), which greatly limits the availability of therapeutic drugs to the tumor. Ultrasound-mediated BBB opening provides a promising approach to help deliver drugs to brain tumors. The use of temozolomide (TMZ) in the clinical treatment of GBM has been shown to be able to increase survival in patients with GBM, but this improvement is still trivial. In this study, we developed a liposomal temozolomide formulation (TMZ-lipo) and locally delivered these nanoparticles into GBM through ultrasound-mediated BBB opening technology, significantly suppressing tumor growth and prolonging tumor-bearing animal survival. No significant side effects were observed in comparison with control rats. Our study provides a novel strategy to improve the efficacy of TMZ against GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available